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Evidence supports a role of antibody-dependent
cellular cytotoxicity (ADCC) toward transitional epi-
topes in the first and second constant (C1-C2) re-
gions of gp120 (A32-like epitopes) in preventing
HIV-1 infection and in vaccine-induced protection.
Here, we describe the first successful attempt at
isolating the inner domain (ID) of gp120 as an inde-
pendent molecule that encapsulates the A32-like re-
gion within a minimal structural unit of the HIV-1 Env.
Through structure-based design, we developed ID2,
which consists of the ID expressed independently of
the outer domain and stabilized in the CD4-bound
conformation by an inter-layer disulfide bond. ID2
expresses C1-C2 epitopes in the context of CD4-trig-
gered full-length gp120 but without any known
neutralizing epitope present. Thus, ID2 represents a
novel probe for the analysis and/or selective induc-
tion of antibody responses to the A32 epitope region.
We also present the crystal structure of ID2 com-
plexed with mAb A32, which defines its epitope.
INTRODUCTION
Numerous studies have indicated a relevant role for Fc receptor
(FcR)-effector functions including antibody-dependent cellular
cytotoxicity (ADCC) in protective immunity, as these responses
have been shown to correlate with slower progression of HIV dis-
ease (Jia et al., 2013; Wren et al., 2013) or decreased virus repli-
cation. Studies of SIV or SHIV-infected non-human primates,
HIV-1-infected humanized mouse models, and the RV144 clin-Structure 24, 697–70
This is an open access article undical trial have linked ADCC with post-infection control of viremia
and/or the blocking of HIV-1 acquisition, often in the absence of
neutralization (Chung et al., 2014; Fouts et al., 2015; Haynes
et al., 2012; Rerks-Ngarm et al., 2009; Yates et al., 2014). In
particular, the immune correlates analyses of the RV144 trial
associated high ADCC activity (together with low immunoglob-
ulin A levels) and polyfunctional immunoglobulin G3 (IgG3) anti-
bodies (Abs) with a reduced risk of infection, thus potentially
contributing to vaccine efficacy (Chung et al., 2014; Tomaras
et al., 2013; Yates et al., 2014).
Considerable evidence suggests that potent ADCC responses
in humans are directed against A32-like epitopes of the Cluster A
region (Guan et al., 2013) which map to the first and second con-
stant (C1-C2) region of gp120 (reviewed in Lewis et al., 2014;
Pollara et al., 2013; Veillette et al., 2016). These epitopes are
classified based onwhether they are extant on target cells during
viral entry, prior to productive infection of a target cell (entry tar-
gets) or exposed on an infected cell producing virions (release
targets) (Lewis et al., 2014; Pollara et al., 2013). The A32-like en-
try targets become exposed during the initial steps of viral entry
after Env trimers engage the host CD4 receptor and, possibly,
the co-receptor. They persist on newly infected cell surfaces
for extended periods of time (Finnegan et al., 2001, 2002; Men-
gistu et al., 2015) where they have the capacity to mediate
Fc-effector functions in vitro (Guan et al., 2013; reviewed in
Lewis et al., 2014; Pollara et al., 2013; Veillette et al., 2016). In
the context of release targets these epitopes are expressed on
infected/budding cells upon triggering of Env trimer with the
cell surface CD4. Recent studies confirm that monoclonal Abs
(mAbs) recognizing A32-like release targets exhibit considerable
ADCCpotency and are thus capable of eliminating infected cells,
including cells budding HIV-1 (Ferrari et al., 2011; Veillette et al.,
2014b; reviewed in Kramski et al., 2015; Lewis et al., 2014; Pol-
lara et al., 2013; Veillette et al., 2016). The picture is even stron-
ger for vaccine-induced immunity in humans, as the A32-like9, May 3, 2016 ª 2016 The Authors. Published by Elsevier Ltd 697
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epitopes have been linked to protective ADCC responses in the
RV144 vaccine trial (Bonsignori et al., 2012; Haynes et al., 2012).
Moreover, the A32-like Abs synergized with V2-specific Abs
for infectious virus capture and ADCC of both tier-1 and -2 vi-
ruses, suggesting that crosstalk between these two specificities
contributed to vaccine efficacy due to FcR-effector functions
(Pollara et al., 2014).
While A32 region epitopes were shown to be highly immuno-
genic during HIV-1 infection as they become exposed during
transitional rearrangements of the Env trimer bound to CD4 on
nascently or persistently infected cells, efforts to selectively
construct these transitional and conformational targets as stable
protein molecules have been difficult for three reasons. First, this
region is buried inside the Env trimer where it is not accessible (or
poorly accessible) for Ab recognition in the ligand-free closed
state (Kwon et al., 2015; Ray et al., 2014; Sanders et al., 2013).
Second, although the A32 region is exposed on monomeric
gp120, its exposure is stabilized only upon binding soluble
CD4. gp120 is highly dynamic, undergoing large conformational
changes in solution (Guttman et al., 2012), and CD4 triggering is
required for stable formation of these targets in monomeric
gp120 (Fouts et al., 2000). Third, the Cluster A epitope region
is localized exclusively within the inner domain (ID), which is
known to be conformationally more mobile (Finzi et al., 2010;
Guttman et al., 2012; Pancera et al., 2010) than other portions
of the HIV-1 Env (such as the outer domain [OD], which has
successfully been grafted and expressed independently of the
ID) (Joyce et al., 2013; Yang et al., 2004). This makes efforts to-
ward isolating this region into a minimal structural unit highly
challenging.
Here, we describe the first successful attempt at isolating the
ID of HIV-1 gp120 as an independent protein molecule that effi-
ciently encapsulates conformational A32-like epitopes within a
minimal structural unit of Env without the complication of other
known epitope specificities. The ID design was guided by our
atomic-level description of the A32 epitope region gained from
the crystal structures of several A32-like Abs in complexes
with CD4-triggered gp120 (Acharya et al., 2014; Gohain et al.,
2015). Through two phases of structure-based design we devel-
oped ID2, which consists of the ID of the gp120 core stabilized in
the CD4-bound conformation and expressed independently of
the OD. ID2 stably expresses the transitional C1-C2 epitopes
involved in potent FcR-effector responses to HIV-1 as indicated
by physicochemical, antigenicity, and functional testing. The
crystal structure of ID2 in complex with the A32 Fab confirms
its proper folding and represents the first co-crystal structure
of mAb A32, the canonical Ab of the ADCC Cluster A region,
complexed with its cognate Env antigen.
RESULTS
Design and Purification of an Independent Inner Domain
Molecule, ID1
Our previous structural analysis of complexes formed between
A32-like mAbs and the gp120 antigen indicated that A32-like
mAbs invariantly recognize the epitope surface around the b1,
b2 strands and the a0 and a1 helices of layers 1 and 2 of the
ID of gp120 in its CD4-bound conformation (Acharya et al.,
2014; Gohain et al., 2015). Residues of the variable loops and698 Structure 24, 697–709, May 3, 2016the OD are not involved in binding. Based on this information,
we hypothesized that an independent ID molecule, with the
V1V2 loop deleted and preferentially stabilized in the CD4-bound
conformation, would be a suitable minimal structure for pre-
senting A32-like epitopes with the same antigenic features as
seen in gp120-CD4 complexes. Our initial design was based
on an observation that the unliganded extended gp120 core
(coree) tends to spontaneously adopt the CD4-bound conforma-
tion (Dey et al., 2009; Kwon et al., 2012). We developed a stable
ID construct of clade A/E isolate 93TH057, which is composed
of a gp120 coree sequence with the OD sequence (residues
258–472, HxBc2 numbering) replaced within ID layer 3 by a
simple -GG- dipeptide linker (Figure 1). The first design of the
independent ID molecule is referred to as ID1. A synthetic ID1
gene was fused to the signal peptide sequence, placed into
the pCMV6-A-puro expression vector, expressed by transient
transfection of 293T cells, and purified as described in Experi-
mental Procedures and Figure S1.
mAbA32 is capable of binding unligandedgp120, butCD4 trig-
gering significantly enhances its exposure and stability in the
context of the single-chain protein (Coutu and Finzi, 2015;
Guan et al., 2013). As a prelude to testing ID1, we tested binding
of Cluster A mAbs including mAb A32, and the anti-Cluster A
mAbs N5-i5, N60-i3, 2.2c, and JR4 (Guan et al., 2013) to mono-
meric full-length BaL gp120 (gp120BaL) and to the single-chain
gp120BaL-sCD4 complex (full-length single-chain [FLSC])
(Fouts et al., 2000) by surface plasmon resonance (Table 1). All
mAbs tested showed increased affinities for the gp120-CD4
complex as shown by an 8- to 32-fold lower affinity constant
(KD) for FLSC compared with unliganded gp120. In all cases,
the increased affinity for the gp120BaL-sCD4 complex resulted
from the faster association rates and reduced dissociation rates,
confirming that the epitopes in the C1-C2 region are indeed
inducible and stabilized in the context of gp120 triggered by
CD4. Next we tested ID1 with the same Ab set to test how the
C1-C2 region epitopes are preserved within the ID1 construct.
As shown in Table 1, ID1 bound effectively to each of five mAbs
tested,with aKD value in a rangeof 1.1–9.3 nM, thuswith affinities
comparablewith or slightly improved over that of gp120 (KD value
in a range of 2.0–12.0 nM). This indicates that ID1 preserves the
antigenic properties of gp120 and is folded to display A32-
like epitopes. To our knowledge, ID1 represents a first stable
construct of the gp120 ID expressed independently of the OD.
Structural Characterization of ID1 in Complex with
Anti-Cluster A mAb JR4
To assess how ID1 is folded, we determined the crystal structure
of ID1 in complex with the Fab of JR4, a C1-C2-specific mAb
recognizing the A32-C11 mixed epitope within the Cluster A re-
gion (Gohain et al., 2015). The structure of Fab JR4-ID1 complex
was solved at 1.85 A˚ with one copy of complex present in the
asymmetric unit of the crystal. The calculated electron density
maps showed clearly defined density for the whole JR4 Fab
and for 104 of 169 residues of ID1 (Table 2).
The overall structure of JR4 Fab-ID1 complex is shown in Fig-
ure 2. ID1 preserves well the overall fold of the ID as in the gp120
coree. The seven-stranded b sandwich is fully folded, the b2
and b4 strands, and three (C54-C74, C218-C247, C228-C249) out
of four disulfide bonds are defined and formed as in the gp120
Figure 1. Design of Inner Domain Constructs
(A) Subsequent steps of design of the independent IDmolecule. Left: structure of gp12093TH057 coree in CD4-bound conformation (fromPDB code: 4H8W);middle
and right: the putative ID1 and ID2 structure. ‘‘Layered’’ architecture of gp120 inner domain is shownwith the seven-stranded b sandwich colored violet, layer 1 in
yellow, layer 2 in cyan, layer 3 in light orange. The outer domain is shown in gray. Asn-proximal NAG residues of glycosyl group and disulfide bonds of ID are
shown as balls and sticks. The -GG(A)- linkers are shown in black. The gp120 surface engaged in binding to the C1-C2 region-specific mAbs is shaded in red.
(B) Sequence of ID constructs of 93TH057 isolate. The -GG- linkers and C65-C115 disulfide introduced to ID1 sequence are shown in red.
See also Figure S1.coree. On the other hand, large portions (38.5%) of the ID1
molecule are disordered in the complex and not resolved in the
structure. These include sequences forming the a0 helix in the
gp120 coree (residues A
58KAHETEVHNVWA70), the first and
second -GG- linker (I109SLWDQSLQPCVKLT-GG-SVIKQACP
KISFD211 and P253VVSS-GG-GNIKDNW479, including the fourth
C119-C205 disulfide of the ID, respectively) and the C-terminal
residues (E492PLGI496) of ID1 (Figures 1B and 2A). The JR4 Fab
anchors ID1 mainly through its heavy chain (85.0% of the Fab
buried surface area [BSA] of the complex) and by contacting
the residues of layer 1 (75.2% of the ID1 BSA, Table S1)
(Figure 2A).
To determine whether the JR4 mixed A32-C11 epitope is pre-
served within the ID1 molecule, we compared the JR4 Fab-ID1
complex with the previously determined crystal structure of the
ternary complex formed by the JR4 Fab, the gp120 coree and
the CD4 mimetic M48 (Gohain et al., 2015) (Figures 2B and
2C). As shown in Figure 2B, large portions of layers 1 and 2 of
the ID, forming the structural framework for the JR4 epitope
within the CD4 mimetic-triggered gp120 coree, are disordered
in the JR4 Fab-ID1 complex. These include the parts of the
b2-a0-connecting coil (residues A58KAH) and a0 helix (residuesE64VHNVWA) of layer 1 and a1 helix (residues N98NMVEQM-
QEDV), and the b2-, b3-strand and V1V2-stem region of layer 2.
In addition, the b1 strand (residues A74CV) of layer 1, which in
the gp120 coree is adjacent to the a0 helix, is not formed in the
ID1 molecule. Overall, the interactive surface that becomes
buried due to the JR4 Fab-ID1 interaction encompasses a total
of 1,930 A˚2 (953 A˚2 contributed by ID1 and 977 A˚2 by Fab); this
is 410 A˚2 smaller than the interactive surface buried at JR4 Fab-
gp12093TH057 coree interface (BSA of 2,340 A˚
2 with 1,195 A˚2
buried by gp120 coree and 1,145 A˚
2 by Fab). Several layer-1 con-
tacts are missing in the JR4-ID1 complex compared with JR4-
gp120 complex, specifically the JR4 heavy chain contacts to
layer 1 (Figures 2C and S2). The missing contacts can be attrib-
uted to disorder in the ID1 structure. The similarity in the A32-
like Ab affinities for ID1 and gp120 suggest that the disordered
residues in ID1, specifically the a0 helix and parts of the a1 helix,
might mirror disorder in full-length gp120 in the absence of CD4.
Structure-Based Design of ID2 and Evaluation of Its
Antigenic Properties
Structural analysis of the Fab JR4-ID1 complex revealed that the
conformational CD4i epitopes of the A32-like region are not fullyStructure 24, 697–709, May 3, 2016 699
Table 1. Binding Kinetics of mAb A32, N5-i5, N60-i3, JR4, and 2.2c to the FLSC, gp120, and ID1 as Measured by Surface Plasmon
Resonance
gp120BaL FLSC Fold Difference ID1 Fold Difference
a Fold Differenceb
mAb A32
KD (M) 3 10
9 3.2 ± 0.07 0.23 ± 0.01 13.9 9.30 ± 1.10 2.9 40.4
ka (1/M s) 3 10
5 1.39 ± 0.02 4.43 ± 0.01 3.2 0.85 ± 0.04 1.6 5.2
kd (1/s) 310
5 43.7 ± 0.99 10.2 ± 0.09 4.3 78.50 ± 5.20 1.8 7.7
mAb N5-i5
KD (M) 3 10
9 5.03 ± 0.03 0.29 ± 0.14 17.3 1.10 ± 0.16 4.6 3.8
ka (1/M s) 3 10
5 0.72 ± 0.01 8.25 ± 2.50 11.5 4.50 ± 1.00 6.3 1.8
kd (1/s) 310
5 36.0 ± 0.28 23.8 ± 13.80 1.5 48.30 ± 4.30 1.3 2.0
mAb N60-i3
KD (M) 3 10
9 2.03 ± 0.07 0.25 ± 0.01 8.0 3.50 ± 0.13 1.7 13.8
ka (1/M s) 3 10
5 2.53 ± 0.06 12.4 ± 0.00 4.9 4.30 ± 0.25 1.7 2.9
kd (1/s) 310
5 51.2 ± 0.50 31.4 ± 0.71 1.6 148 ± 2.70 2.9 4.7
mAb JR4
KD (M) 3 10
9 2.34 ± 0.16 0.18 ± 0.01 13.0 6.00 ± 0.33 2.6 33.3
ka (1/M s) 3 10
5 2.62 ± 0.09 6.43 ± 0.06 2.5 1.60 ± 0.10 1.6 4
kd (1/s) 310
5 61.1 ± 1.80 11.6 ± 0.28 5.3 94.40 ± 0.60 1.5 8.1
mAb 2.2c
KD (M) 3 10
9 12.00 ± 0.07 0.50 ± 0.06 24.0 3.00 ± 0.30 4 6.0
ka (1/M s) 3 10
5 0.73 ± 0.01 11.5 ± 1.40 15.7 2.70 ± 0.16 3.7 4.3
kd (1/s) 310
5 87.5 ± 1.10 55.6 ± 14.40 1.6 80.30 ± 2.40 1.1 1.4
aFold difference relative to gp120.
bFold difference relative to FLSC.formed within ID1, with regions around the V1V2 stem and a0
helix flexible and not contributing to anti-Cluster A mAb binding.
We hypothesized that adding a disulfide bond at the bases of
a0 and a1 helices could restore and preserve CD4i epitopes in
this region (Figure 1). Accordingly, we mutated V65 and S115 to
cysteines to form a single disulfide bond at the a0- and a1-helix
junction. Similar mutations have been shown to increase CD4i
epitope exposure in the context of full-length gp120 (Kassa
et al., 2013). This revised second independent ID molecule,
with the V1V2 stem removed and stabilized by a C65-C115 disul-
fide bond, was designated ID2.
We tested the affinity of ID2 for a panel of anti-Cluster A mAbs
using surface plasmon resonance (Figure 3 and Table S2). ID2
bound the panel of mAbs tested with an average of 17-fold
tighter affinities than ID1, and similar or higher than those of
FLSC (Figure 3A). The increase in affinity was largely attributable
to an increase in ka for the complex and to a lesser extent a
decrease in kd, suggesting that ID2 more closely resembles
the CD4-bound conformation of gp120 recognized by these
mAbs. To further determine that ID2 is folded to stably present
the A32-like epitopes in solution, we tested the binding of mAb
A32 to ID2 by isothermal titration calorimetry (ITC) and compared
it with themAbA32 interaction with FLSC (Figure 3B). These data
clearly indicate that ID2 adopts a CD4-bound conformation in
solution that closely resembles the presentation of the A32-
epitope in CD4-trigerred gp120. The binding kinetics of mAb
A32 to ID2 and FLSC are very similar, with KD values of 9.0
and 11.5 nM and DH of 2.553 (±0.18) and 3.15 (±0.69)
kcal/mol for the mAb A32-ID2 and mAb A32-FLSC interactions,700 Structure 24, 697–709, May 3, 2016respectively. Finally, we also testedwhether ID2 is recognized by
A32-like mAbs isolated from RV144 vaccinees (Bonsignori et al.,
2012) and mouse mAbs specific for C1-linear epitopes poorly
exposed within the properly folded gp120 preparations (Abacio-
glu et al., 1994; Moore et al., 1994b) (Table S3). Whereas RV144
mAbs bound efficiently to ID2 with affinities comparable with
anti-Cluster A mAb JR4, the peptide specific mAbs B18 and
C4 failed to recognize ID2. Altogether, these data confirm that
ID2 stably presents the desired conformational epitopes within
the C1-C2 gp120 region and shows the antigenicity profile of
the CD4-triggered gp120.
Structural Characterization of ID2 in Complex with
mAb A32
To confirmwhether ID2 preserves the Cluster A epitopes of CD4-
triggered gp120 better than ID1, we determined its crystal struc-
ture in complexwithmAbA32Fab (Experimental Procedures; Ta-
ble 2; Figure 4 and S3). The structural characterization of the ID2
complex fully validated its design. As shown in Figure 4A, ID2 fully
preserves the fold of the ID of the gp120 coree in its CD4-bound
conformation with the seven-stranded b sandwich and all the
secondary structural elements of layers 1 and 2 (including a0
and a1 helices) present and arranged to form the C1-C2 epitope
as seen in complexes of A32-like mAbs with CD4-triggered
gp120 corese (Acharya et al., 2014; Figures 1 and 4A). Most of
the ID2molecule is defined in the complex (85% of themolecule,
compared with 61% for ID1, Figure S4) with the only unresolved
regions mapping to the N and C termini (residues 42–44 and 492)
and to the introduced flexible -GGA- and -GG- linkers (residues
Table 2. Data Collection and Refinement Statistics
Fab
JR4-ID1
Fab
A32-ID2293 HEK Cells
Fab
A32-ID2E. coli
Data Collection
Wavelength (A˚) 0.9795 1.128 0.9795
Space group C222(1) P2(1)2(1)2 P2(1)2(1)2
Cell parameters
a, b, c (A˚) 78.5, 89.9,
180.8
75.7, 208.2,
73.2
75.8, 211.8,
72.9
a, b, g () 90, 90, 90 90, 90, 90 90, 90, 90
Complexes (a.u.) 1 2 2
Resolution (A˚) 50–1.85
(1.88–1.85)
50–3.10
(3.15–3.10)
50.0–3.00
(3.05–3.00)
No. of reflections
Total 299,100 165,660 119,799
Unique 51,569 19,959 20,655
Rmerge
a (%) 10.7 (100) 18.6 (95.5) 16.3 (88.0)
I/s 15.0 (1.1) 14.6 (1.3) 9.5 (1.2)
Completeness (%) 94.9 (91.4) 93.2 (96.8) 87.1 (86.7)
Redundancy 5.8 (5.7) 8.3 (8.3) 5.8 (5.8)
Refinement Statistics
Resolution (A˚) 50–1.85 50–3.1 50–3.02
Rb (%) 18.6 23.2 22.7
Rfree
c (%) 22.3 28.9 28.8
No. of atoms
Protein 4,034 8,470 8,600
Water 376 0 4
Ligand/ion 32 0 0
Overall B value (A˚2)
Protein 44.7 95.8 90.2
Water 42.4 – 61.7
Ligand/ion 47.5 – –
RMSD
Bond lengths (A˚) 0.018 0.010 0.008
Bond angles () 1.79 1.53 1.45
Ramachandrand
Favored (%) 8.9 87.5 87.0
Allowed (%) 8.9 9.4 9.4
Outliers (%) 0.5 3.1 3.6
PDB 5FCU 4YBL 4YC2
Values in parentheses are for highest-resolution shell.
aRmerge =
PjI  <I>j/PI, where I is the observed intensity and <I> is
the average intensity obtained from multiple observations of symmetry-
related reflections after rejections.
bR =
PkFoj  jFck/
PjFoj, where Fo and Fc are the observed and calcu-
lated structure factors, respectively.
cRfree as defined by Bru¨nger (1992).
dCalculated with MolProbity.117–118, 206–209, 254–256, and 472–474). Each of the four di-
sulfide bonds (including the newly introduced C65-C115 disulfide
bond) are defined and maintained as predicted. The structural
alignment of ID2 from the Fab A32-ID2 complex with the gp120
coree (from Fab N5-i5-gp12093TH057 coree-d1d2CD4; Acharyaet al., 2014) and with ID1 resulted in a root-mean-square devia-
tion (RMSD) between main-chain atoms of 0.76 A˚ (523 atoms)
and 1.36 A˚2 (416 atoms), respectively, indicating a closer similar-
ity of the overall structure of ID2 to the ID in the CD4-triggered
gp120 corese bound to A32-like mAbs, than to ID1.
The A32 Fab-ID2 complex also represents the first co-crystal
structure of mAb A32 with its cognate gp120 antigen. mAb A32,
similar to A32-likemAbs N5-i5, JR4, and N60-i3 described previ-
ously in complexes with gp120 corese, binds exclusively within
the C1-C2 regions of gp120 (Figure 4B). Its epitope is formed
by bridging mobile layers 1 and 2 with anchoring points centered
on the b2 strand, the a0 helix, and b1 strand, and the a1 helix (res-
idues 51–54, 60–61, 69, and 71–78 [layer 1] and 103, 106–107,
110, 113–114, 217, and 220–221 [layer 2]) (Figures 4B and 4C).
The interactive surface that becomes buried at the Fab A32-ID2
interface is 1,701 A˚2 (856 A˚2 contributed by Fab and 845 A˚2
by ID2, Table S1). Most of the Fab contacts are contributed
by its heavy chain, with complementarity-determining region
(CDR) H3 making contacts to the b2 strand of gp120 (residues
T51LFC) and CDR H1–3 contacting the residues of the a0 helix
and the b1 strand (e.g., W69ATHACVP motif). In contrast, con-
tacts to the a1 helix of layer 2 are almost exclusively contributed
by two arginines of CDRH3 (R99 andR100B) with someminor con-
tributions from the CDR L1, CDR H1, and the FWR1 (Figures 4B
and 4C). The A32 paratope is electropositive largely due to three
arginines, R97, R99, andR100B,whichmakeup75%of theCDRH3
BSA and approximately 50% of the heavy chain BSA (Table S1).
In addition to complementing the electronegative gp120 epitope,
these three electropositive residues simultaneously bind layers 1
and 2 and stabilize the gp120 conformation in much the same
way as the C65-C115 disulfide bond.
Of the four anti-Cluster A Abs characterized to date in com-
plexes with gp120 (Acharya et al., 2014; Gohain et al., 2015),
mAb A32 shares the most similar mode of antigen recognition
with mAb N60-i3. mAb A32 and N60-i3 share 78% and 83%
sequence identity in their heavy- and light-chain variable (V)
domains, respectively (70.1% identity for the CDRs alone) and
recognize gp120 with striking similarities (Figure 5). They
approach the antigen through the same angle and utilize the
same CDR contacts to interact with their cognate epitopes.
The close structural similarity of the Fab-antigen interfaces is re-
flected in a relatively low RMSD value of 1.80 A˚2 calculated for
main-chain atoms of the V domains of A32 and N60-i3 and ID2
and the corresponding gp120 coree residues, respectively. The
major difference between mAb A32 and N60-i3 and other A32-
like mAbs is the stronger reliance of mAb A32 on its interaction
with the a1 helix in layer 2 of the ID (Figure 5 and Table S1).
ID2 Fully Preserves Functional Epitopes of the C1-C2
Region of gp120
ID2 represents the first stable design of the gp120 ID expressed
independently of theODandstabilized in aCD4-bound confirma-
tion to exclusively express the non-neutralizing, ADCC epitopes
of theC1-C2 region.Thebindinganalysis indicates that anti-Clus-
ter A mAbs bind to ID2 with affinities comparable with that of the
gp120-CD4 complex; thus the desired epitopes are preserved
within the ID2 design (Figure 3). Additionally, to test whether ID2
engrafts epitopes involved in Fc-effector functions directed to
theC1-C2 regionofHIV-1Env,weperformedacompetitionassayStructure 24, 697–709, May 3, 2016 701
Figure 2. Crystal Structure of the JR4 Fab-ID1 Complex
(A) The JR4 Fab-ID1 complex and its 180 view about a vertical axis are shown in a ribbon diagram with the molecular surface displayed over the residues of the
Fab involved in ID1 binding (right). The structural gp120 elements engaged in JR4 Fab binding—the b2-,b4 strand and the a1 helix—are labeled.
(B) Structural comparison of JR4 Fab-ID1 and JR4 Fab-gp12093TH057 coree-M48 complexes. Complexes were aligned based on the ID of gp120 and are colored
in darker and lighter shades for JR4 Fab-ID1 and the JR4 Fab-gp120 interface, respectively.
(C) JR4 epitope footprints on ID1 and the gp120coree. The gp120 residues buried at the complex interface are shown as spheres and displayed over the ribbon
diagram of ID1 and the gp120coree. The gp120 residues that contribute to JR4 Fab binding in JR4 Fab-gp12093TH057 coree-M48 complex but are not involved in
JR4 Fab binding to ID1 are shown in red.
See also Figure S2 and Table S1.in which effector functions of anti-Cluster A mAbs were tested
at their effective concentrations in the presence of increasing
concentrations of ID2. The assay was performed using two com-
plementary methods: the rapid fluorimetric (RF)-ADCC assay
(Gomez-Roman et al., 2006), which measures trogocytosis
(e.g., Fc-effector function mediated by CD14+ monocytes) rather
thanADCC (Kramski et al., 2012), and the flowcytometry (fluores-
cence-activated cell sorting [FACS])-based ADCC assay, which
allows the quantification of cell killing by ADCC (e.g., mediated
by natural killer [NK] cells) (Richard et al., 2014). As shown in
Figure 6A, ID2 completely inhibited of all of the A32-like mAbs
tested in the (RF)-ADCC assay and as well as the mixed A32-
C11 mAb JR4 at a concentration range of 0.1–10 mg/ml. The
Fc-effector activity of mAb C11, which recognizes an epitope
involving residues of N andC termini and seven-stranded b sand-
wich of gp120 (Gohain et al., 2015) not present within the ID
design, was minimally affected. The same pattern of inhibition
of mAb A32 and C11 was observed in the FACS-based ADCC
assay (Figure S4). Together, these data confirm that ID2 is folded
to stably display functional A32-like and mixed A32-C11-like
epitopes within the ADCC Cluster A region.
Next, we tested how efficiently ID2 can adsorb Abs present in
HIV+ sera and compete with their ADCC activities. It was shown702 Structure 24, 697–709, May 3, 2016previously that infected individuals frequently elicit Abs spe-
cific for A32-like epitopes and that the predominant fraction
of the ADCC response in sera from HIV-1-infected individuals
is directed at epitopes exposed on the CD4-triggered gp120
core including the A32 region (e.g., according to Ferrari et al.,
[2011], pre-incubation of target cells with Fabs of A32 and 17b
blocked about 50% of the ADCC activity in 7 of 14 HIV-1-in-
fected individuals). As shown in Figure 6B, we pre-incubated
HIV+ sera (20 samples of sera derived from HIV-1-infected indi-
viduals including both progressors and long-term non-progres-
sors as characterized in Table S4) with either a D368R gp120
dV1V2V3V5 mutant or ID2 protein before being assayed for their
ability to bind to CEM.NKr cells infected with a NefVpu virus
(Figure 6B, left) and to mediate ADCC (Figure 6B, right). We
used viruses lacking Nef and Vpu (i.e., presenting high levels of
CD4 and Env at the cell surface) to ensure effective exposure
of A32-like targets on the infected cell surface as described
by Ferrari et al. (2011) and Veillette et al. (2015). The D368R
gp120 dV1V2V3V5 mutant, bearing CD4i epitopes of gp120
core, was previously shown to almost completely abrogate
cell-surface staining and ADCC of Nef-Vpu-infected cells (Ding
et al., 2015; Veillette et al., 2015). ID2 specifically bound Abs
present in HIV+ sera and adsorbed approximately 30% of total
Figure 3. Binding of Cluster A Abs to ID2
(A) Bar graph for binding affinity (KD) of Cluster A mAbs to FLSC (blue), gp120BaL (red), ID1 (green), and ID2 (purple). The inset represents a magnified view of the
higher binding affinity section of the graph. Units are in nM.
(B) ITC curves for A32 IgG against FLSC and ID2.
See also Table S2.ADCC activity. The levels of observed ADCC competition
are with agreement with previous observations indicating that
A32 epitopes constitute a large fraction but not the only fraction
of ADCC targets in sera of infected individuals (Ferrari et al.,
2011; Veillette et al., 2015). Altogether these data indicate that
ID2 stably engrafts the epitopes recognized by A32-like Abs
involved in ADCC from the sera of HIV-1-infected individuals.
DISCUSSION
The A32-like epitopes of the Cluster A region map exclusively
within the inner domain of the gp120 (Acharya et al., 2014;
Gohain et al., 2015), on the gp120 face that interacts with the
gp41 ectodomain in the trimeric structure of the HIV-1 Env (Pan-
cera et al., 2014; Yang et al., 2003; York and Nunberg, 2004). On
the native trimer of most HIV-1 isolates, this region is buried
at the trimer interface and is inaccessible for Ab recognition until
the interaction with the target cell receptor and, possibly, the
co-receptor (reviewed in Lewis et al., 2015; Veillette et al.,
2016). Our recent studies indicate that substantial structural
rearrangements of the ID are required to convert to the confor-
mation recognized by A32-like Abs from the Ab-inaccessible
native, untriggered trimeric Env (Acharya et al., 2014). More-
over, accumulating evidence suggests that exposure of these
epitopes on the virion spike strictly depends on binding cell
surface anchored CD4, since triggering with soluble CD4 does
not lead to exposure of these epitope targets on virion-associ-
ated HIV-1 trimers (Acharya et al., 2014; Mengistu et al., 2015;
Ray et al., 2014).
In this report we describe a newmolecule, ID2, which consists
of the ID of HIV-1 gp120 expressed independently of the OD and
stabilized to effectively express the conformational C1-C2 region
epitopes. To our knowledge, we are the first to successfully
isolate the ID of gp120 as an independent and fully stable mole-
cule. In the past, the isolation of this gp120 region into a minimal
structural unit was thought to be highly challenging or impos-
sible, mostly due to the fact that the ID is highly mobile and
undergoes pronounced conformational rearrangements duringthe structural transitions of the HIV-1 Env trimer in the viral entry
process (Pancera et al., 2014; Yang et al., 2003). A stable ID
construct of HIV-1 gp120 was developed, expressed in both
mammalian and bacterial systems, and characterized by struc-
tural and functional means. Through two phases of rational
structure-based design, we obtained the ID2 molecule, which
displays the A32-like epitopes within a minimal structural unit
of gp120 consisting of 167 residues and constrained by the en-
gineered C65-C115 bond to adopt a CD4-bound state. ID2 stably
expresses the C1-C2 epitopes as indicated by significantly
increased or comparable affinities for anti-Cluster A mAbs
compared with unliganded gp120 or gp120-CD4 complexes,
respectively. Structural analysis of ID complexes with A32 and
JR4 mAbs fully validated the ID design. ID1, the first ID design,
consisting of ID as in gp120 corees (Dey et al., 2009; Kwon
et al., 2012), failed to adopt the CD4-bound conformation
required for formation of CD4i epitopes of A32-like region. ID1
displayed antigenic properties of full-length untriggered gp120
and the epitope of anti-Cluster AmAb JR4was only partially pre-
served within its design, as indicated by large portions of the JR4
binding surface being disordered in the Fab JR4-ID1 complex.
Regions of the ID1 molecule found to be disordered in the Fab
JR4-ID1 complex were previously shown to undergo a signifi-
cant conformational change upon CD4 binding, evident in the
comparisons of CD4-bound gp120 coree structures (Acharya
et al., 2014; Kwon et al., 2012) with the recent gp140 SOSIP tri-
mers (Julien et al., 2013; Lyumkis et al., 2013; Pancera et al.,
2014). We were able to eliminate the ID1 disorder and fully
induce the CD4i A32-like region in the ID2 design that incorpo-
rates truncations of the V1V2 stem region and a new C65-C115 di-
sulfide bond. The C65-C115 bond links the a0 (layer 1) and a1
(layer 2) helices and thus stabilizes the ID in the CD4-bound
conformation. We show here the ID2 construct, which is based
on the clade A/E 93TH057 virus sequence, but we were also
able to obtain stable ID2 preparations using sequences of other
clades including clade B strain YU2. Both of these preparations
preserve antigenic properties of ID2 of clade A/E 93TH057 (Table
S5), confirming that the ID2 design is a durable structuralStructure 24, 697–709, May 3, 2016 703
Figure 4. Crystal Structure of A32 Fab-ID2 Complex
(A) A32-ID2 complex (left) and its 180 view about a vertical axis are shown in ribbon diagram with molecular surface displayed over the residues of the Fab
involved in ID2 binding (right). See also Figure S3 and Table S1.
(B) Details of the A32 Fab-ID2 interface. A32 Fab contacts on ID2 and ID2 contacts on the A32 Fab are shown as balls displayed over the ID2/A32 Fab ribbon
diagram and highlighted in black over the ID2/A32 Fab electrostatic potential surface. The A32 Fab contacts are shown in dark purple, light purple, and purple for
heavy, light, and both chain(s) contacts, respectively. The ID2 contacts through residues of layer 1, layer 2, and both are shown in yellow, cyan, and gray,
respectively.
(C) A32 Fab and ID2 contact residues on the primary sequence of ID2 and A32 Fab, respectively. Residues contributing to the A32 Fab-ID2 interface as defined by
PISA (Krissinel and Henrick, 2007) are highlighted, and contacts as defined by a 5-A˚ cutoff are marked above the sequence. Side-chain (+) and main-chain ()
contacts are colored based on contact type; hydrophobic in green, hydrophilic in blue, or both in black.template and can be used to generate other independent ID
molecules based on sequences of any HIV-1 strain.
ID2 abrogates entirely Fc-mediated effector function of A32
and A32-like mAbs and specifically adsorbs ADCC activities
against target CEM.NKr T cells infected with NefVpu NL4.3
virus from the sera of HIV-1-infected individuals. It was shown
previously that CD4i Env epitopes, including targets within the
A32 region, are preferentially recognized by Abs capable of
potent ADCC present in sera (Ferrari et al., 2011; Richard
et al., 2014; Veillette et al., 2014a, 2014b, 2015) or cervico-
vaginal lavages (Batraville et al., 2014) of HIV-1-infected indi-
viduals. ID2 is therefore folded to stably display the functional704 Structure 24, 697–709, May 3, 2016epitopes of the C1-C2 region. It is designed to engraft non-
neutralizing A32-like epitopes selectively without any other
known epitopes, especially those involved in neutralizing Ab
response. By design ID2 consists of two faces: a face harboring
the C1-C2 epitopes and a face exposed by the removal of the
OD that does not harbor any known epitope targets (Figure 1).
As a minimal structural unit of gp120 effectively expressing the
A32-like region, ID2 has significant translational value because
it can be employed as a specific probe for the analysis of
Ab responses to these non-neutralizing epitope targets (e.g., in
immune correlates analysis of future vaccine trials or epitope
mapping). It also constitutes a novel immunogen candidate,
Figure 5. Comparison of A32 Fab-ID2 and N60-i3 Fab-gp12093TH057coree-M48U1 Complexes
Complexes superimposed based on the gp120 ID are shown with light/heavy chain of A32 Fab and N60-i3 Fab is colored in light/dark purple and green,
respectively. A 45 view shows the details of A32 Fab-ID2 and N60-i3-gp120coree. The molecular surfaces are displayed over the ID2 and gp120coree surfaces,
and CDRs of Fabs with residues contributing to the binding are shown.selectively and stably presenting the ADCC A32-like epitopes
that could be used in challenge studies to address the exclusive
role of non-neutralizing Abs in vaccine protection. We previously
showed that many of the residues forming the Cluster A epitope
are highly conserved among HIV isolates (Acharya et al., 2014;
Gohain et al., 2015; Guan et al., 2013), indicating that ADCC
responses specific for this region will be cross-reactive and
undergo limited immune escape. As such, they represent an
important vaccine target. Anti-Cluster A mAbs also share similar
characteristics in their V domains, with moderate length CDR H3
loops and a low degree of VH chain maturation (Acharya et al.,
2014; Gohain et al., 2015; Guan et al., 2013). Thus, ID2 can
potentially be used to elicit anti-Cluster A Abs in vivo without
intensive immunization regimens and without immunogens
designed and optimized to recognize an affinity-matured Ab
variant. Studies are under way to evaluate ID2 as an immunogen
capable of selective induction of the A32-like responses in ani-
mal hosts.
Finally, our studies are the first to define the structure of the
epitope of mAb A32, the canonical mAb of the Cluster A region.
The previous reports were based solely on binding studies with
Envmutants associated the A32 epitope primarily with the C1 re-absence or presence of 10 mg/ml DV1V2V3V5 D368R or 2.66 mg/ml ID2 for 30 min
experiments. Statistical significance was tested using paired one-way ANOVA (*gion of gp120 (Finzi et al., 2010; Moore et al., 1994a; Pancera
et al., 2010). Our Fab A32-ID2 complex represents the first co-
crystal structure of mAb A32 with its gp120 antigen and permits
the precise description of the gp120-binding footprint of mAb
A32. Accordingly, mAb A32 recognizes a conformational epitope
formed by the b2 strand, the a0 helix and b1 strand, and the a1
helix of the gp120 ID. mAb A32 binds to gp120, almost entirely
overlapping the footprint and mimicking the binding mode of
the mAb N60-i3, a human Ab isolated from an HIV-1-infected in-
dividual of our natural virus suppressor cohort (Gohain et al.,
2015). Thus, it recognizes the same discontinuous site within
the C1-C2 region as other anti-Cluster A mAbs described previ-
ously to be capable of potent FcR-effector function against
gp120-coated and virus-bound target cells (Acharya et al.,
2014). The A32 epitope, like epitopes of other anti-Cluster A
mAbs (Acharya et al., 2014; Gohain et al., 2015), is buried inside
the HIV-1 Env trimer where it is not accessible (or poorly acces-
sible) for Ab recognition in the ligand-free closed state (Mengistu
et al., 2015; Ray et al., 2014; Sanders et al., 2002, 2013). Thus,
our work provides a structural understanding of why mAb A32
does not efficiently recognize and inactivate (through an ADCC
mechanism) target cells infected with wild-type HIV-1 viruses.Figure 6. Functional Properties of ID2
(A) ID2-competition of Fc-mediated effector func-
tions of anti-Cluster A mAbs. The activities of
Cluster A mAbs (at concentrations corresponding
to IC75) in (RF)-ADCC assay were measured in the
presence of increasing concentrations of ID2 pro-
tein using gp120-coated EGFP-CEM-NKr-CCR5-
SNAP cells as targets and PBMCs as effector cells.
(B) ADCC competition of Abs in sera from HIV-
infected individuals. CEM.NKr cells infected with
NL4.3 ADA.GFP NefVpu virus were used at 48 hr
post-infection for surface staining of Abs bound
(left) and an RFADCC assay (right) using sera
from HIV-1-infected individuals pre-incubated in
at room temperature. Data shown are representative of at least three different
*p < 0.01, ****p < 0.0001).
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The HIV-1 accessory viral protein U (Vpu) and negative regula-
tory factor (Nef) protein, two well-established regulators of cell-
surface CD4 expression, reduce the levels of CD4 on the surface
of the infected target (reviewed in Veillette et al., 2016). In the
absence of CD4, the HIV-1 Env trimers remain in the ligand-
free closed state, inhibiting the effective recognition of infected
cells by mAb A32 (Richard et al., 2015; Veillette et al., 2014b,
2015). Utilization of the full potential of mAb A32 and other Abs
targeting A32 region epitopes to inactivate infected cells through
an FcR mechanism in vivo will be possible only if effective
strategies capable of diminishing the CD4-downregulation effect
are developed and implemented.
EXPERIMENTAL PROCEDURES
Inner Domain Design
ID1 consists of residues 44–123 (HxBc2 numbering) and 199–256 of gp120
connected by a glycine-glycine linker that is, in turn, connected to the C termi-
nus of gp120 (residues 472–496) by another glycine-glycine linker to remove
the OD. ID2 was made based on the ID1 sequence in which the V1V2 region
(residues 118–206) was replaced by a two-glycine alanine linker. ID2 was
further stabilized by adding an extra disulfide by mutating V65 and S115 to cys-
teines. Initial clones were synthesized with optimized codons for mammalian
expression using the native gp120 leader sequence. Mutations were added
with the Quikchange PCR mutagenesis kit (Stratagene) as per the manufac-
turer’s protocol.
Protein Expression and Purification
IDs were expressed by transfection using the FreeStyle 293T and GnT1 293T
Mammalian Expression System (Invitrogen) for functional and structural anal-
ysis, respectively, and according to the protocol provided by the manufac-
turer. IDs were purified using an N5-i5 IgG affinity column. N5-i5 IgG was
chemically crosslinked to protein A resin using the Pierce Protein A IgG Plus
orientation kit (Thermo Fisher Scientific). Protein bound to the N5-i5 IgG affinity
column was eluted with 0.1 M glycine (pH 3.0) and immediately diluted 10:1
with 1 M Tris-HCl (pH 8.5).
ID2 for co-crystallization studies was grown in the Origami (DE) Escherichia
coli strain (Novagen). ID2 sequence was cloned into the pMal-c5e expression
vector (New England Biolabs) with an N-terminal maltose-binding protein
(MBP)-thioredoxin tag followed by a six-histidine tag and a thrombin cleavage
sequence. The cell lysate (after 2–3 min of sonication and centrifugation at
12,000 3 g for 30 min) was loaded onto a HiTrap nickel column (GE Health-
care). MBP-thioredoxin-ID2 was eluted with 25 mM Tris-HCl (pH 8.0) and
500 mM imidazole (pH 8.0). The MBP-thioredoxin tag was removed by diges-
tion overnight at 4Cwith agarose-linked bovine thrombin (Sigma) and passing
the lysate over an amylose column. Flow-through fractions were concentrated
and purified further using an N5-i5 IgG affinity column as described above.
Crystallization and Data Collection
For structural studies the ID proteins were deglycosylated with 10 units/mg of
Endo Hf (NE Biolabs) for 3–4 hr at 37C. Endo Hf was removed by passing the
sample over the column of amylose resin (NE Biolabs).
Fab fragments were generated from IgG by papain cleavage using papain-
linked agarose slurry (G Biosciences). Fabswere purified by passing the digest
over a HiTrap protein A column (GE Healthcare), followed by gel filtration chro-
matography in a Hiload Superdex200 16/60 column (GE Healthcare) equili-
brated with 5 mM Tris-HCl (pH 8.5) and 150 mM NaCl.
Fab-ID complexes for crystallization experiments were made by mixing pu-
rified Fab and ID protein at a 1:1.5 M ratio and incubating on ice for 30 min.
Complexes were purified by gel filtration chromatography in a Hiload Super-
dex200 16/60 column (GE Healthcare) equilibrated with 5 mM Tris-HCl
(pH 8.5) and 150 mMNaCl. Crystals were grown by the hanging-drop method.
Combinations of Fabs of Cluster A mAbs A32, N5-i5, N60-I3, and JR4 were
used to prepare complexes with ID1 and ID2 and tested for crystal formation.
Only complexes forming diffraction-quality crystals, which include Fab
JR4-ID1 and Fab A32-ID2 complex, were selected for further analysis. Fab706 Structure 24, 697–709, May 3, 2016JR4-ID1 complex crystals were grown from 20% polyethylene glycol (PEG)
momomethyl ether, 0.2 M ammonium sulfate, and 0.1 M Tris-HCl (pH 7.5).
Fab A32-ID2 complex crystals were grown from 18% to 22% PEG 6000 or
PEG 8000 and 0.1 M Tris-HCl (pH 8.5). JR4 and A32 complex crystals were
flash-frozen in liquid nitrogen after a brief soak in the crystallization condition
supplemented with 20% and 15% MPD, respectively.
Diffraction data were collected at the Stanford Synchrotron Radiation Light
Source at the beam lines BL12-2 (Fab JR4-ID1 and Fab A32-ID2E. coli) and
BL7-1 (Fab A32-ID2293 cells), equipped with MAR325, PILATUS 6M PAD, and
ADSC Quantum 315 area detectors, respectively. All data were processed
and reduced with HKL 2000 (Otwinowski et al., 1997).
Structures were solved by molecular replacement with Phaser (McCoy,
2007) from the CCP4 suite based on the coordinates of gp120 (PDB: 4H8W),
and the JR4 Fab (PDB: 4RFE) and A32 Fab (PDB: 3TNM). Refinement was car-
ried out with Refmac (Murshudov et al., 1997) and Phenix (Adams et al., 2002).
Refinement was coupled with manual refitting and rebuilding with Coot (Ems-
ley and Cowtan, 2004). The first Fab A32-ID2 structure was solved using ID2
grown in 293HEK cells. The structure was refined to an Rc/Rfree of 23.2/28.9
with several residues of the complex missing and not built into a model due
to the lack of interpretable experimental densities (Table 2). New crystals
were grown with ID2 expressed from an E. coli expression system to improve
the quality of the diffraction data. These crystals diffracted to a resolution of
3.0 A˚ and had the same crystallographic space group as crystal form 1, but
were not isomorphous. Well-defined experimental densities obtained from
these data allowed us to unambiguously build 133 out of 156 residues of ID2
in the complex (Table 2 and Figure S4).
Surface Plasmon Resonance Analysis
The binding affinity and kinetics of ID constructs to mAb A32, N5-i5, N60-i3,
JR4, and 2.2c were assessed by surface plasmon resonance on a Biacore
T-100 (GE Healthcare) at 25C. The kinetic constants were determined using
a 1:1 Langmuir model of binding with BIAevaluation software (GE Healthcare).
ITC Analysis
ITC was used to characterize the interaction of FLSC and ID2 with A32 IgG
using an iTC200 instrument (GE Healthcare). Titrations were performed at
25C. Heats of dilutions were measured and subtracted from each dataset.
All data were analyzed using Origin 7.0 software.
Competition of Fc-mediated Effector Function of Anti-Cluster A Abs
with ID2
Measurements were performed using the RF-ADCC assay (Gomez-Roman
et al., 2006) and FACS-based assay (Richard et al., 2014). In the RF-ADCC
assay, EGFP-CEM-NKr-CCR5-SNAP target cells were stained with SNAP-
Surface Alexa Fluor 647 (NE Biolabs) with or without HIV-1Bal gp120
(50 mg/ml). mAbs tested (at fixed concentrations corresponding to their IC75
value) were mixed with ID2 (serially diluted 1:3, from 10 mg/ml to 0.5 ng/ml)
and incubated with gp120-sensitized targets for 15 min at room temperature.
The human effector peripheral blood mononuclear cells (PBMCs, obtained
from healthy donors) were added at a ratio of 50:1 (effector/target cell). After
2 hr of incubation at 37C in 5% CO2, cells were washed, fixed in 1% parafor-
maldehyde, and samples were collected on a BD Fortessa Special Order
instrument (BD Biosciences) and analyzed using FlowJo software (Tree Star).
Serum Adsorption and ADCC Competition Assays
Written informed consent was obtained from all study participants (the
Montreal Primary HIV Infection Cohort), and research adhered to the ethical
guidelines of CRCHUM and was reviewed and approved by the CRCHUM
institutional review board (ethics committee). Cells and viruses (NL4.3
ADA.GFP NefVpu) were used as previously described to infect CEM.NKr
cells (Richard et al., 2014; Veillette et al., 2014b, 2015). Sera derived from
HIV-1-infected individuals, both progressers and long-term non-progressors
as described and characterized in Table S4, were pre-incubated for 30 min
at room temperature with either purified soluble D368R dV1V2V3V5 gp120
or ID protein at a concentration of 10 mg or 2.66 mg protein/ml of serum, respec-
tively, before being assayed for their ability to bind to infected cells and
mediate their ADCC-dependent elimination as previously described (Richard
et al., 2014; Veillette et al., 2014b, 2015).
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